1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

The FACT Act Statement

fact_act_voteOver the last few months, there has been a great deal of discussion about the Furthering Asbestos Claim Transparency Act (H.R. 982) also known as the FACT Act. The FACT Act just passed the House of Representatives by a vote of 221-199.  The bill requires the existing asbestos trusts to file quarterly reports on the claims they have received.

The Mesothelioma Applied Research Foundation, after difficult consideration, has chosen not to take an official stand on the FACT Act. Mary Hesdorffer, the executive director of the Foundation, and Melinda Kotzian, its chief executive officer, consulted the Foundation’s board of directors and its major supporters, and uniformly decided that the FACT Act falls outside of the mission of the Meso Foundation.

“We are a research foundation focused on developing effective treatments and a cure for mesothelioma,” stated Ms. Kotzian, “Taking a stand on legal issues falls outside our scope of work and outside of our expertise.” As it reads in our policy on litigation:

Our primary function is to support the health needs of the patient. Involvement in tort and litigation issues does not fall into this category, nor is it our area of expertise. For this reason, it is our position that we will abstain from commenting on or supporting legislation that does not directly address the health needs of mesothelioma patients and their loved ones. 

Read the full text of the Mesothelioma Applied Research Foundation’s policy on litigation.

View the text of the bill, search HR 982 on Thomas: www.thomas.gov

See who voted / didn’t vote for the FACT Act: http://clerk.house.gov/evs/2013/roll579.xml

Also...

In Other News

Clinical Trials

Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different

Read More »

Peritoneal Surgery/HIPEC

Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC).  This session

Read More »

Share:

Facebook
Twitter
LinkedIn